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Abstract The production of autoantibodies to citrullinated
type II collagen and the citrullination of type II collagen
were analyzed in rheumatoid arthritis. Autoantibodies to
citrullinated type II collagen were detected in 78.5% of
serum samples from 130 rheumatoid arthritis patients.
Autoantibodies to native noncitrullinated type II collagen
were detected in 14.6% of serum samples, all of which were
positive for anti-citrullinated type II collagen antibodies.
Serum samples were also positive for anti-citrullinated type
II collagen antibodies in 1 of 31 systemic lupus erythemato-
sus patients and 2 of 55 patients with osteoarthritis of the
knee. In contrast, sera samples from 24 systemic sclerosis
patients, 21 dermatomyositis/polymyositis patients, 21
ankylosing spondylitis patients, and 18 psoriatic arthritis
patients were all negative for anti-citrullinated type II col-
lagen antibodies. Anti-citrullinated type II collagen anti-
bodies and fragments of citrullinated type II collagen were
found in the synovial ﬂuid obtained from affected knee
joints of 15 rheumatoid arthritis patients. Moreover, anti-
citrullinated type II collagen antibodies were isolated from
the synovium of affected knee joints in 8 rheumatoid arthri-
tis patients using antigen/antibody immunocomplex
dissociation buffer but not by using standard buffers.
These ﬁndings indicate that autoantibodies that react with
citrullinated type II collagen are speciﬁcally produced
and that immunocomplexes composed of fragments of
citrullinated type II collagen and autoantibodies are depos-
ited in the inﬂamed articular synovium in rheumatoid
arthritis patients. Assaying for the presence of anti-
citrullinated type II collagen antibodies may therefore be
useful for diagnosing rheumatoid arthritis, and the deposi-
tion of these immunocomplexes in the articular synovium
may be involved in pathogenesis.
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Introduction
Rheumatoid arthritis (RA) is associated with citrullination,
which is the conversion of arginine residues into citrulline
residues. This process is catalyzed by the enzyme
peptidylarginine deiminase (PADI). Citrullination plays an
important role in protein degradation, as molecular interac-
tions that are mediated by positively charged arginine resi-
dues are lost upon citrullination.
1,2  Citrullinated proteins
have been found in the synovium of RA patients.
3 More-
over, four single nucleotide polymorphisms (SNPs) have
been identiﬁed in the exons of the PADI type 4 (PADI-4)
gene in RA patients. Susceptible PADI-4 messenger RNA
(mRNA) including four SNPs is signiﬁcantly more stable
than nonsusceptible mRNA.
4,5  PADI-4 is primarily ex-
pressed in granulocytes, where expression is generally in-
duced by nonspeciﬁc inﬂammation and lasts for a few days.
2
PADI-4 protein presumably leaks out of granulocytes fol-
lowing cell death and then goes on to citrullinate proteins or
degraded peptides in affected RA joints.
Individuals with RA frequently have autoantibodies to
citrullinated peptides derived from ﬁlaggrin or ﬁbrin.
6–9
However, the involvement of these autoantibodies in RA
pathogenesis remains unclear, since ﬁlaggrin is not present
in articular joints and ﬁbrin is not a joint-speciﬁc molecule.
Because type II collagen is a major and speciﬁc molecule in
articular joints, we investigated whether this protein is
citrullinated and whether autoantibodies react with
citrullinated type II collagen in sera and joint ﬂuids of RA
patients.
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Patients and methods
Subjects
Serum samples were obtained from patients with RA and
were stored at −80°C until use. Diagnosis and anatomical
staging of the disease were established according to the
American Rheumatism Association (ARA) criteria. Of 130
patients (24 men and 106 women; mean age, 56.2 ± 12.4
years), 24 were classiﬁed as stage I, 46 as stage II, 41 as stage
III, and 19 as stage IV according to the Steinbrocker
classiﬁcation. Serum samples were also obtained from 14
patients with polyarticular-type juvenile rheumatoid arthri-
tis (JRA), 31 systemic lupus erythematosus (SLE) patients,
24 systemic sclerosis patients, 21 dermatomyositis/polymyo-
sitis patients, 21 ankylosing spondylitis patients, 18 psoriatic
arthritis patients, and 55 patients with osteoarthritis (OA)
of the knee. Diagnoses of these patients were established
according to their respective clinical criteria. Forty healthy
donors (11 men and 29 women; mean age, 53.8 ± 16.4 years)
provided serum samples as controls.
Synovial ﬂuid samples were obtained from 15 patients
with RA (3 men and 12 women; mean age, 61.2 ± 8.7 years;
11 stage II, 4 stage III [Steinbrocker classiﬁcation]), and 41
patients with OA (9 men and 32 women; mean age, 68.3 ±
5.1 years) by aspiration from knee joints at the outpatient
clinic of the Jikei University hospital, and were stored at
−80°C until use. Synovial samples were obtained from 8
patients with RA (2 men and 6 women; mean age, 52.7 ± 5.5
years; all stage II [Steinbrocker classiﬁcation]) and 11 pa-
tients with OA (3 men and 8 women; mean age, 63.6 ± 5.4
years) by resection from supra-patella pouches of the knee
joints during synovectomy performed in the Jikei Univer-
sity hospital, and were stored at −80°C until use. Informed
consent was obtained from all donors and patients, and
approval by the ethical committee of the university and the
institutional review board were also obtained.
Preparation of citrullinated type II collagen
Human type II collagen was isolated from articular cartilage
as described by Miller.
10 Purity of isolated type II collagen
was conﬁrmed by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS-PAGE), by Coomassie blue
(Bio-Rad) staining, and by Western blotting with anti-
human type II collagen antibody (Chemicon International,
Temecula, CA, USA) (Fig. 1). Isolated human type II col-
lagen was dissolved with 0.5M AcOH by vortexing at a
concentration of 1.0mg/ml, and the solution was then dis-
solved in reaction buffer (0.1M Tris–HCl [pH 7.6], 10mM
CaCl2, and 5mM DTT) at a concentration of 30µg/ml. Type
II collagen was then citrullinated by incubation with
peptidylarginine deiminase (PADI) (Sigma, St. Louis, MO,
USA) at a concentration of 1 unit/ml for 1h at 50°C. After
citrullination, the PADI was excluded by spin-column.
Citrullination of type II collagen was conﬁrmed by Western
blotting with anti-citrulline antibody (Biogenesis, Poole,
UK) (Fig. 1).
Assay for anti-citrullinated type II collagen antibodies
Detection of anti-citrullinated type II collagen antibodies
was performed by enzyme-linked immunosorbent assay
(ELISA) using buffered normal rabbit serum (NRS) as a
blocking agent to diminish nonspeciﬁc binding of human
IgG to the plastic plates, as previously described.
11 Each
well of the ELISA plate (Serocluster U plates; Costar,
Cambridge, MA, USA) was coated with citrullinated type
II collagen by incubation with 100µl solution dissolved in
phosphate buffer (pH 7.6) at a concentration of 5µg/ml
overnight at 4°C. Serum, ﬂuid samples, or synovial extracts
were diluted 1:50 in buffered NRS and added to the plates.
The secondary antibody, peroxidase-conjugated rabbit anti-
human IgG (Fc speciﬁc; Cooper Biochemical, Cochranville,
PA, USA) was diluted 1:2000 with 25% NRS. The assay
was performed with the standard technique and the plates
were read at a wavelength of 490nm using 630nm as a
reference. All samples were tested in duplicate, and the
results were averaged. For the sera assay, the median and
standard deviation (SD) of the OD490 values of sera from
healthy donors were determined after the distribution of
OD490 values was standardized using BoxCox conversion.
Sera with an OD490 that was greater than the median + 2 ×
SD of controls were considered positive. The cutoff value
was 0.16. For the joint ﬂuid and synovial extract assays,
OD490 values in OA samples were used as controls and the
cutoff values were 0.2 and 0.10, respectively. Control serum
was included on all plates to monitor plate-to-plate varia-
tion. Variation never exceeded 5%, and values were there-
fore not corrected.
Inhibition studies were performed by preincubating sera





Fig. 1A–C. Human type II collagen was isolated from articular carti-
lage as described in Patients and methods. Purity of the isolated type II
collagen was conﬁrmed by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis using Coomassie blue staining (A) and Western blot-
ting with anti-human type II collagen antibody (B). Isolated human
type II collagen was citrullinated as described in Patients and methods.
Citrullination of human type II collagen was conﬁrmed by Western
blotting using anti-citrulline antibody (C)278
at a concentration of 20µg/ml overnight at 4°C. The OD490
signal of the blank was deﬁned as 100% inhibition, and the
original OD490  signal in the ELISA was deﬁned as 0%
inhibition.
Isolation of anti-citrullinated type II collagen antibodies
from the synovium
Synovial samples were cut into small pieces and washed
with Tris buffer containing 0.1% Tween-20. Synovial pieces
were then homogenized with ImmunoPure Gentle Ag/Ab
Elution Buffer (Pierce, Rockford, IL, USA) at neutral pH
to dissociate the antigen/antibody immunocomplexes de-
posited in the synovium or were homogenized with Tris
buffer or phosphate buffer as a negative control. After
centrifugation and collection of supernatants, ImmunoPure
Gentle Ag/Ab Elution Buffer was substituted with Tris
buffer using a Centricon Centrifugal Filter Device
(Millipore, Bedford, MA, USA). Liquid samples were
then concentrated at 10µl/1.0g of wet weight volume of
synovium using a Microcon Centrifugal Filter Device
(Millipore). The procedure described above was performed
at 4°C. The anti-citrullinated type II collagen antibodies in
the synovial extracts were detected by ELISA as described
above.
Isolation and detection of citrullinated type II collagen
fragments in synovial ﬂuids
Synovial ﬂuid samples were applied to an afﬁnity column
conjugated with rabbit polyclonal antibodies directed
against human type II collagen (Chemicon International.)
after hyaluronidase treatment; this was followed by cen-
trifugation to remove debris. ImmunoPure Gentle Ag/Ab
Elution Buffer was applied onto the column after washing
with Tris buffer, and the elution buffer was then collected
and desalted using a Centricon Centrifugal Filter Device.
The elution buffer was then freeze-dried and completely
solubilized in the sample buffer (50mM Tris–HCl, pH 6.8,
2% (w/v) SDS, 10% (w/v) glycerol, with 6% β-
mercaptoethanol). Samples were subjected to SDS-PAGE
(10% (w/v) gel) and were transferred to nitrocellulose
membranes. Staining was performed in the manner of stan-
dard technique. Brieﬂy, the blotted membrane was reacted
with rabbit anti-citrulline antibodies (Biogenesis) or with
rabbit anti-type I collagen antibodies as control for 1h at
room temperature after washing with Tris buffer. Then, the
membrane was reacted with the secondary anti-rabbit
IgG antibodies conjugated with alkaline phosphatase
(Chemicon International) for 30min at room temperature
after washing with Tris buffer three times. The immune
complexes were visualized with the NBT/BCIP staining
solution (Roche; Mannheim, Germany) according to the
manufacturer’s instructions after washing with Tris buffer
three times. Ten synovial ﬂuid samples obtained from 10 of
15 RA patients (9 stage II and 1 stage III [Steinbrocker
classiﬁcation]) were analyzed. Fluid samples obtained from
OA patients were not analyzed in the present study.
Results
Anti-citrullinated type II collagen antibodies in RA sera
Of the 130 RA serum samples assayed, 102 (78.5%) were
positive for autoantibodies that reacted with citrullinated
human type II collagen (Fig. 2). The reactivity of these sera
with citrullinated type II collagen was more than 80% inhib-
ited by the antigen, with the exception of one sample, of
which reactivity was the strongest compared to the other
samples (Fig. 2). No signiﬁcant differences were observed in
the incidence of anti-citrullinated type II collagen antibod-
ies between sera from patients with different stages of RA.
Antibodies to native noncitrullinated type II collagen were
detected in 19 (14.6%) serum samples from 130 RA pa-
tients. All these positive samples were positive for anti-
citrullinated type II collagen antibodies. Anti-citrullinated
type II collagen antibodies were also positive in 11 (78.6%)
of 14 sera from patients with polyarticular type JRA. Of the
sera from 31 patients with SLE, one sample was positive for
autoantibodies, while 2 of the 55 sera samples from patients
with OA of the knee were positive for autoantibodies. All
sera samples from the 24 systemic sclerosis patients, 21
dermatomyositis/polymyositis patients, 21 ankylosing
spondylitis patients, and 18 psoriatic arthritis patients were
negative for anti-citrullinated type II collagen autoantibod-
ies (Fig. 3).
Anti-citrullinated type II collagen antibodies in synovial
ﬂuids
Of the 15 RA synovial ﬂuid samples assayed, 13 (86.7%)
were positive for anti-citrullinated type II collagen antibod-
ies, and the reactivity of these samples with citrullinated
type II collagen was more than 80% inhibited by the anti-
gen (Fig. 4). Anti-citrullinated type II collagen antibodies
were positive in all sera obtained from the 15 RA patients
who donated synovial ﬂuids.
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Fig. 2. The assay for detecting anti-citrullinated type II collagen anti-
bodies was performed in 130 serum samples from patients with rheu-
matoid arthritis (RA) and 40 serum samples from healthy donors. The
transverse line shows the cutoff value. For the positive sera from RA
patients, an inhibition assay was performed using citrullinated type II
collagen as antigen. O.D., OD490 value279
Anti-citrullinated type II collagen antibodies in synovial
extracts
All eight synovial extracts from RA patients that were ho-
mogenized with the antigen/antibody immunocomplex dis-
sociation buffer were positive for anti-citrullinated type II
collagen autoantibodies, and the reactivity of these synovial
extracts with citrullinated type II collagen was more than
80% inhibited by the antigen (Fig. 5). Synovial extracts
from RA synovium homogenized with Tris or phosphate
buffer were all negative. Anti-citrullinated type II collagen
antibodies were all positive in sera obtained from the eight
RA patients from whom synovium was extracted.
Fragments of citrullinated type II collagen in synovial
ﬂuids
Afﬁnity chromatography using polyclonal anti-human type
II collagen antibodies revealed protein bands correspond-
ing to a molecular weight of approximately 55kDa and less
than 20kDa that reacted with anti-citrulline antibodies in
all 10 synovial ﬂuid samples isolated from the knee joints of
RA patients (Fig. 6).
Discussion
Type II collagen is a major and speciﬁc molecule in articular
cartilage. In the present study, we found that type II col-
lagen was citrullinated in the affected joints of patients with
RA and that autoantibodies to citrullinated type II collagen
were speciﬁcally produced in these patients. Moreover,
autoantibodies to citrullinated type II collagen were iso-
lated from the inﬂamed articular synovium of RA patients
using antigen/antibody immunocomplex dissociation buffer
but not by standard Tris or phosphate buffer. These ﬁndings
indicate that immunocomplexes composed of fragments of
citrullinated type II collagen and autoantibodies were
formed and deposited in the inﬂamed articular synovium of
RA patients. Although it is unclear whether these
immunocomplexes are involved in the induction of arthritis,
it is known that systemic administration of a mixture of
monoclonal anti-type II collagen antibodies induces arthri-
tis in mice,
12 that major cytokines expressed in the articular
synovium of RA patients, interleukin-1 and tumor necrosis
factor-α, are predominantly expressed in the arthritic joints
of these mice,
13 and that the immunocomplexes deposited in
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Fig. 3. The assay for detecting anti-citrullinated type II collagen anti-
bodies was performed in 55 serum samples from patients with osteo-
arthritis (OA) of the knee, 31 systemic lupus erythematosus (SLE)
patients, 24 systemic sclerosis (SS) patients, 21 dermatomyositis/poly-
myositis (DM) patients, 21 ankylosing spondylitis (AS) patients, and 18
psoriatic arthritis (PA) patients. The transverse line shows the cutoff
value
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Fig. 4. The assay for detecting anti-citrullinated type II collagen anti-
bodies was performed in 15 synovial ﬂuid samples obtained from af-
fected knee joints of rheumatoid arthritis (RA) patients and 41 synovial
ﬂuid samples obtained from knees of osteoarthritis (OA) patients. The
transverse line shows the cutoff value. For all samples from RA knees,
an inhibition assay was performed using the citrullinated type II col-
lagen as antigen
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Fig. 5. Extracts were obtained from the synovium of affected knees of
8 rheumatoid arthritis (RA) patients and 11 osteoarthritis (OA) pa-
tients using the buffer for the dissociation of antigen/antibody
immunocomplex, and the assay for anti-citrullinated type II collagen
antibodies was performed. The transverse line shows the cutoff value.
For all samples from RA patients, an inhibition assay was performed
using citrullinated type II collagen as antigen280
these tissues activate the complement cascade, which is one
of the ﬁrst steps in the induction of inﬂammation. There-
fore, these ﬁndings support the idea that the formation and
subsequent deposition of citrullinated type II collagen-
autoantibody immunocomplexes in the synovium are in-
volved in disease pathogenesis in RA patients, although
there is a possibility that the immunocomplexes including
the other citrullinated peptides except type II collagen also
correlate the disease pathogenesis of RA.
Recently, it has been reported that the serological detec-
tion of antibodies to the cyclic citrullinated peptide (CCP),
which is a modiﬁed peptide variant of a citrullinated
ﬁlaggrin epitope, is quite signiﬁcant in RA diagnosis.
8,14,15
An assay of CCP antibody of second generation was later
established and the sensitivity and speciﬁcity of the assay
were 66%–88% and 89%–98%, respectively.
16–20 The sensi-
tivity and speciﬁcity of the anti-citrullinated type II collagen
antibody assay were approximately 79% and 95%, respec-
tively. Thus, the anti-citrullinated type II collagen antibody
assay may become one of the signiﬁcant tools for diagnosis
of RA, although the sensitivity of the assay is less than that
of the CCP antibody assay of second generation.
Conclusion
Type II collagen appears to be citrullinated in the joints of
RA patients, causing the production of autoantibodies
against citrullinated type II collagen. The formation and
subsequent deposition of immunocomplexes composed of
anti-citrullinated type II collagen antibodies and
citrullinated type II collagen fragments in the articular
synovium may thus be involved in the pathogenesis of RA.
Assaying for the presence of anti-citrullinated type II col-
lagen antibodies may therefore have a signiﬁcant role to
play in diagnosing RA.
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Fig. 6A,B. Fragments of type II collagen were isolated from the syn-
ovial ﬂuid of knees of 10 RA patients by afﬁnity chromatography using
polyclonal antibodies against human type II collagen. These isolated
fragments were then separated by sodium dodecyl sulfate–polyacryla-
mide gel electrophoresis. A  Western blotting was performed using
anti-citrulline antibodies. Fragments of citrullinated type II collagen
were found in all 10 samples at a molecular weight of approximately
55kDa and less than 20kDa. B Western blotting was performed with
anti-type I collagen antibodies as control
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